Will Big Pharma get the bug for microbiome therapies?

The microbiome therapeutics field is dominated by many innovative small and medium-sized enterprises (SMEs), all focused on driving the development of a single or a small pipeline of biotherapeutics. This has resulted in an impressive range of innovative products in development, often targeting conditions which conventional “small molecule” drug discovery projects have failed to adequately address.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Law firm expands by relocating Ireland office

15 February 2023 The move is part of a strategic plan, with a focus on patents.

Biotechnology

Microbial consortia and IP in Europe

23 August 2022 Protecting new and inventive innovations in this increasingly crowded area is essential, explains Ine Vanderleyden of Mewburn Ellis.

Americas

Ferring wins Nocdurna patent suit with ex-employee

25 August 2020 Swiss-based Ferring Pharmaceuticals has prevailed in a patent dispute with rivals Serenity Pharmaceuticals and Reprise Biopharmaceuticals over a nighttime urination, or nocturia, treatment.